MedTrace Logo

11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension

NCT01917136 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2019-02-05

Study results available
· View outcomes & findings →

Summary

This study is looking at differences in metabolism and functional imaging between pulmonary hypertension subjects with normal right ventricular function and persistent right ventricular dysfunction.

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

11C-acetate

For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate

DRUG

[18F]Fluoro-2-deoxy-2-D-glucose

For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG

OTHER

Cardiac MRI

Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.

Sponsors & Collaborators

  • University of Pennsylvania

    lead OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • University of Maryland

    collaborator OTHER

  • Yale University

    collaborator OTHER

  • Washington University School of Medicine

    collaborator OTHER

  • The Cardiovascular Medical Research and Education Fund

    collaborator OTHER

Principal Investigators

  • Yuchi Han, MD · University of Pennsylvania

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2018-10-31
Completion
2018-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01917136 on ClinicalTrials.gov